# A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC

Source: https://onco.cc/trials/nct05918133/  
OnCo record `nct05918133` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of PM8002 in triple-negative breast cancer, run by Biotheus Inc., active and no longer recruiting.

## Summary

A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC is a phase 1/2 interventional study registered as NCT05918133 by Biotheus Inc., with 42 participants enrolled, started 2022-07-01 and due to reach its primary completion in 2026-10-30. Interventions recorded: PM8002 and nab-paclitaxel.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05918133
- Phase: 1/2
- Setting: A Phase Ib/II Study of PM8002 Injection Plus Nab-paclitaxel as First Line Therapy for Unresectable, Locally Advanced or Metastatic Triple-negative Breast Cancer
- Sponsor: Biotheus Inc.
- Enrolled: 42

## Sources

- ClinicalTrials.gov NCT05918133: https://clinicaltrials.gov/study/NCT05918133

## Connected records

- cancers: [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- drugs: [PM8002](https://onco.cc/drugs/pm8002/)
- companies: [BioNTech](https://onco.cc/companies/biontech/)

---
JSON: https://onco.cc/api/v1/entities/nct05918133.json